home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Lavie Bio announces commercial expansion of Yalos as seed treatment for soybean, following successful field trials


Rehovot, Israel
November 12th, 2024 

Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season 

Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the commercial expansion of Yalos® seed-treatment to soybean, following successful field trials performed in 2024 in the US.  Yalos®, Lavie Bio’s first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean.

Yalos® is comprised of two novel microbes that together improve early vigor, biomass, root and shoot development, and nutrient availability. It aims to improve emergence and establishment and increase farm productivity through advanced biological technologies. Currently, Yalos® is sold in North America as a seed-treatment for spring and winter wheat, durum and barley, distributed in Canada by Winfield United and in the US directly by Lavie Bio. As of spring 2025, Lavie Bio intends Yalos® to be commercially available for soybean as well.

Soybean represents an additional 86 million acres in market potential for Yalos® in the US alone[1]. This expansion more than doubles the potential market for Yalos® compared to markets in which Lavie Bio already operates.

Throughout the soybean field trial series, Yalos® has repeatedly demonstrated increased crop vigor, improved establishment and plant health, consistently supporting its effective performance. The trials took place in US soybean growing regions, representing different varieties and soil conditions, showing an average increase in soybean yield of more than 5%, a significant improvement in this crop.

“The addition of soybean to crops effectively treated by Yalos® is a significant achievement,” stated Amit Noam, Lavie Bio’s CEO. “We are very pleased with the results and are excited to bring innovation to soybean growers across North America. With Yalos’® winter wheat positive results, on which we announced earlier this year, and with the current promising results in soybean, Lavie Bio is looking forward to a global expansion of Yalos® into Brazil and European markets in the coming years”.

[1] https://www.nass.usda.gov/Publications/Todays_Reports/reports/acrg0624.pdf

 



More news from: LaVie Bio Ltd.


Published: November 12, 2024

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section


Copyright @ 1992-2025 SeedQuest - All rights reserved